


antagonist activity is a non-competitive NMDA receptor antagonist.

12. (amended) [Pharmaceutical] The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor antagonist activity is a compound of formula I [defined in claim

3]



where:

R¹ and R² are independently phenyl or 4-fluorophenyl;

R³ is hydrogen, C₁₋₆ alkyl or methoxycarbonyl;

R⁴ is hydrogen or methyl;

and metabolites and isomers thereof both as a free base and pharmaceutically acceptable salts thereof.

REMARKS


Claims 1-12 are pending in the application. Claims 1-3 and 9-12 have been amended. The amendments reflect the amendments submitted by Applicants on July 21, 2000 during prosecution in the International Stage. Other amendments have been made in the

interest of correcting certain informalities. No new matter has been introduced by any of the amendments herein.

The Assistant Commissioner is hereby authorized to charge any fees which may be due in connection with this communication to Deposit Account No. 23-1703.

Dated: October 27, 2000

Respectfully submitted,



Richard J. Sterner
Reg. No. 35,372

Applicants' Agent
Customer No. 007470
(212) 819-8200

Agent's Direct line:
(212) 819-8783

000001-55048660